4-(Furan-2-yl)-2,6-dioxocyclohexane-1-carbaldehyde | 92132-91-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(Furan-2-yl)-2,6-dioxocyclohexane-1-carbaldehyde
• CAS: 92132-91-7
• 化学式: C₁₁H₁₀O₄
• 分子量: 206.19
• InChiKey: SSANUYXFMPOACI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Method of determining vasoreactivity using inhaled nitric oxide
  申请人：VERO BIOTECH LLC

  公开号：US11154210B2

  公开（公告）日：2021-10-26

  A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.

  一种治疗患者肺动脉高压的方法可包括确定肺动脉高压患者是否存在右心室扩大或右心室功能障碍，其中患者之前已服用过类固醇，如果患者没有右心室扩大或右心室功能障碍，则让患者停用类固醇。
• METHOD OF DETERMINING VASOREACTIVITY USING INHALED NITRIC OXIDE
  申请人：Geno LLC

  公开号：EP2713723B1

  公开（公告）日：2018-09-12
• [EN] METHOD OF DETERMINING VASOREACTIVITY USING INHALED NITRIC OXIDE<br/>[FR] PROCÉDÉ DE DÉTERMINATION DE LA VASORÉACTIVITÉ À L'AIDE D'OXYDE NITRIQUE INHALÉ
  申请人：GENO LLC

  公开号：WO2012166534A1

  公开（公告）日：2012-12-06

  A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.
• [EN] MU-OPIOID RECEPTOR BINDING COMPOUNDS<br/>[FR] COMPOSÉS SE FIXANT AU RÉCEPTEUR DES OPIOÏDES DE TYPE MU
  申请人：ALGYNOMICS INC

  公开号：WO2012166891A2

  公开（公告）日：2012-12-06

  A pharmaceutical composition, comprising (i) a mu opioid receptor modulating compound selected from the group consisting of Group I compounds, Matching Compounds, and their pharmaceutically acceptable derivatives, (ii) a pharmaceutically acceptable carrier, and (iii) optionally, another therapeutic agent. Also described are therapeutic methods of administering mu opioid receptor modulating compounds, and cocktail formulations with other mu opioid receptor compounds, e.g., morphine, (+)-morphine, methadone, (+)-methadone, 3-methoxynaltrexone, etorphine, or naltrexone.